has function has role vaccinated in route immunizes against disease immunizes recipient melanoma Homo sapiens melanoma vaccine subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role therapeutic cancer vaccine PD-L1 peptide vaccine NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148146 6338 NCT: https://clinicaltrials.gov/study/NCT03042793 29126 Gene name: PD-L1 A cancer vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. The vaccines aims to stimulate PD-L1 specific T-cells, hence eliminating both PD-L1 positive tumor cells as well as PD-L1 positive immunosuppressive and antigen presenting cells in the tumor microenvironment. It has been used in clinical trials for patients with multiple melanoma. Jie Zheng cancer vaccine Hayleigh Kahn VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6338